Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma

INTRODUCTION: Temozolomide (TMZ) is the first-line chemotherapeutic option to treat glioma; however, its efficacy and clinical application are limited by its drug resistance properties. Polo-like kinase 1 (PLK1)-targeted therapy causes G2/M arrest and increases the sensitivity of glioma to TMZ. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Hui, Sun, Shuo, Xu, Haoyue, Zhao, Zongren, Han, Zhengzhong, Jia, Jun, Wu, Dongmei, Lu, Jun, Liu, Hongmei, Yu, Rutong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229804/
https://www.ncbi.nlm.nih.gov/pubmed/32494134
http://dx.doi.org/10.2147/IJN.S243878

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229804/
https://www.ncbi.nlm.nih.gov/pubmed/32494134
http://dx.doi.org/10.2147/IJN.S243878

Ejemplares similares